ScientiaLux
Index
QF-Pro Home › QF-Pro Glossary › Clinical Applications › Precision Medicine
Clinical Applications — Step 5 of 5
1Clinical Utility
2Patient Stratification
3Melanoma
4NSCLC
5Precision Medicine
Previous
NSCLC
Concept

Precision Medicine

The vision of matching patients to optimal therapies–where functional biomarkers represent the next frontier.

View
Definition
Precision medicine aims to match each patient with their optimal therapy based on molecular characteristics of their disease. In oncology, this vision has driven development of targeted therapies (imatinib for BCR-ABL, trastuzumab for HER2) and companion diagnostics. Yet for immunotherapyLoading..., precision remains elusive–PD-L1 expression poorly predicts response. Functional biomarkers represent the next evolution: measuring not just molecular presence but biological activity.
Video Segments
Misclassified Patients: The 280% Opportunity
Primary
Related Segments
The 2.13% Clinical Cutoff
Related
Right Drug
For the right patient
Molecular Matching
Biomarker-guided selection
ICI Challenge
Expression biomarkers inadequate
Functional Future
Activity-based biomarkers

The Promise and Reality

Precision medicine has transformed certain cancers. BCR-ABL inhibitors converted CML from fatal to manageable. HER2-targeted therapy dramatically improved breast cancerLoading... outcomes. These successes share a common feature: clear biomarker-drug relationships.

Immunotherapy presents a different challenge. The targets (checkpoints) are normal proteins performing normal functions in the wrong context. Presence doesn't equal pathogenic activity–making expression-based biomarkers fundamentally limited.

Simplified

The Goal: Match each patient with the treatment most likely to work for their specific tumor.

Current Reality: Molecular testing has improved treatment selection, but many patients still receive ineffective treatments. We're not precise enough yet.

The Functional Frontier

Functional biomarkersLoading... address this limitation by measuring protein activity states rather than abundance. For checkpoint immunotherapy, this means quantifying receptor-ligand engagement–the actual biology that checkpoint inhibitors target.

The shift from "is the protein present?" to "is the pathway active?" represents the next evolution of precision medicine. Early validation in melanoma, NSCLC, and renal cell carcinoma demonstrates the clinical potential.

Simplified

What's Missing: Current tests mostly measure what's PRESENT (genes, proteins) rather than what's ACTIVE (pathways, interactions).

The Opportunity: Functional biomarkers add a new dimension—not just "is it there?" but "is it working?" This could enable truly precise treatment matching.

Expression-Based
Is the biomarker present? (genomics, IHC)
Function-Based
Is the pathway active? (FRET, conformational)

Applications of Functional Precision Medicine

  • ICILoading... patient selection: Move beyond PD-L1 expression to checkpoint engagement
  • Combination rationale: Multi-checkpoint profiling guides rational combinations
  • Resistance anticipation: Detect pathway activation patterns predicting escape
  • Drug development: Functional endpoints for novel targeted therapies

Connected Terms

Share This Term
Term Connections